Taken as a whole, these findings indicate that ACP6, FLT4, MANSC1, IFNG, IL17C, and IL32 may be used as promising prognostic biomarkers that distinguish early-stage from advanced CRC. Here, IL32 is linked to colorectal carcinoma.